IKNA - Ikena falls on acquisition of Pionyr in all-stock deal
2023-08-07 14:32:38 ET
More on Ikena Oncology
- Ikena: AACR2023 Validates Their Hippo Pathway Target, But We Need Data
- Ikena Oncology prices $40M offering
- Ikena Oncology prices $40M offering
- Ikena gains on FDA’s fast track status for bladder cancer candidate
- Ikena Oncology wins FDA Fast Track Designation for lead asset
- Seeking Alpha’s Quant Rating on Ikena Oncology
For further details see:
Ikena falls on acquisition of Pionyr in all-stock deal